Mary Gibson, NP
Community Health · Oregon City, ORNPI 1346301918
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $565, 3.5 times the $161 reported in 2021.
Across 71 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$309
- Lilly USA, LLC$171
- Vanda Pharmaceuticals Inc.$157
- Lundbeck LLC$135
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$115
- Takeda Pharmaceuticals U.S.A., Inc.$69
- plus $507 from 16 others
What the payments were for
- Food & beverage$1,464100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$115
How this compares
Too few community health providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 45 | $87,989 |
| MounjaroTirzepatide | 44 | $50,348 |
| TrulicityDulaglutide | 31 | $31,373 |
| XareltoRivaroxaban | 45 | $31,337 |
| OzempicSemaglutide | 23 | $25,326 |
| LinzessLinaclotide | 28 | $15,609 |
| JardianceEmpagliflozin | 12 | $9,888 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $9,379 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $7,559 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,788 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,650 |
| Varenicline Tartrate | 20 | $5,453 |
| Oxycodone Hcl | 194 | $4,082 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 30 | $3,658 |
| Pregabalin | 90 | $3,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $309 | $87,98945 claims |
| Lilly USA, LLCMounjaro, Trulicity | $171 | $81,72175 claims |
| AbbVieLinzess | $13 | $15,60928 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $69 | $6,65014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few community health providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other community health in Oregon City
- Wendy RoweMedford$363
- Eden AldrichBend$123
- Esther BrownSalem$74
- Rachel PoffAlbany$67
- Kendra FalkSpringfield$18
- Deborah YoungPortland$18
- Bridget MurphyCorvallis$18
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.